Drug Approval | March 23, 2024
Briefs: Concord Biotech and Neuland Laboratories
The inspection at Unit 1 by the USFDA has been successfully completed, with no observations under Form 483
The inspection at Unit 1 by the USFDA has been successfully completed, with no observations under Form 483
Operations of Line II was stopped due to a fire incident earlier
Hepatitis B infects over 40 million people in India
Pharma Solutions operates 10 research and development and/or production sites globally
The pilot plant is focused on scaling up beverage production and will support applications
KarXT, Karuna’s lead asset, is a potential first-in-class treatment for Schizophrenia
Lonza plans to invest approximately CHF 500 million to upgrade the facility
The plan essentially was to separate Aster’s India and GCC businesses to unlock long-term value
A five-day inspection was concluded successfully with no critical and no major observations raised
Ukrainian marketing approvals for paclitaxel, oxaliplatin and irinotecan mark a significant milestone in the company’s global expansion strategy
Subscribe To Our Newsletter & Stay Updated
